<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514111</url>
  </required_header>
  <id_info>
    <org_study_id>upeclin/HC/FMB-Unesp-16</org_study_id>
    <nct_id>NCT00514111</nct_id>
  </id_info>
  <brief_title>Factors Associated to Success of Hepatitis C Therapy</brief_title>
  <official_title>Factors Associated to Success of Hepatitis C Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UPECLIN HC FM Botucatu Unesp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UPECLIN HC FM Botucatu Unesp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the sustained virologic response (RVS) in HVC patients
      treated with pegylated-interferon or conventional-interferon and ribavirin, and to
      investigate the associated factors with RVS, by means of retrospective analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis C virus(HVC) is a major public-health problem since it presents a long
      phase of clinical latency which makes its early diagnosis difficult and results in the
      development of a large number of cases to complications such as cirrhosis, hepatic
      insufficiency and hepatocarcinoma. In Brazil, it is estimated three million estimated cases
      to 52 thousand reports. The aim of this study is to evaluate the sustained virologic response
      (RVS) in HVC patients treated with pegylated-interferon or conventional-interferon and
      ribavirin, and to investigate the associated factors with RVS, by means of retrospective
      analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted</condition>
  <arm_group>
    <arm_group_label>HVC Patients</arm_group_label>
    <description>HVC patients attended in SAE e HD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated-interferon, conventional-interferon, ribavirin</intervention_name>
    <description>Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.</description>
    <arm_group_label>HVC Patients</arm_group_label>
    <other_name>Pegasys</other_name>
    <other_name>PegIntron</other_name>
    <other_name>Ribavirin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HVC patients attended in SAE e HD.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HVC patients that received specific treatment with pegylated-interferon or
             conventional-interferon, and ribavirin

        Exclusion Criteria:

          -  No HVC infection or treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre N Barbosa, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPECLIN HC FM Botucatu Unesp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SAE e Hospital Dia de Aids</name>
      <address>
        <city>Botucatu</city>
        <state>Sao Paulo</state>
        <zip>18618970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <last_update_submitted>March 19, 2009</last_update_submitted>
  <last_update_submitted_qc>March 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Naime Barbosa</name_title>
    <organization>SAE e Hospital Dia de Aids - Faculdade de Medicina de Botucatu - Unesp</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

